Mathew Garnett
@mgarnett.bsky.social
Cancer programme Faculty @sangerinstitute.bsky.social & founder MosaicTx developing precision combination therapies. #Cancer, Functional genomics, biomarkers, target discovery, #organoid, #CRISPR. Proud 🇨🇦.
Reposted by Mathew Garnett
Exciting news - we are recruiting new Group Leaders! 🥼
We are seeking to appoint exceptional early-career scientists & clinician scientists as #GroupLeaders to develop bold, innovative, high-impact #CancerResearch programmes
Full details on our website: www.cruk.manchester.ac.uk/career/new-g...
We are seeking to appoint exceptional early-career scientists & clinician scientists as #GroupLeaders to develop bold, innovative, high-impact #CancerResearch programmes
Full details on our website: www.cruk.manchester.ac.uk/career/new-g...
Group Leader Recruitment at the Cancer Research UK Manchester Institute
YouTube video by CRUK Manchester Institute
youtu.be
September 24, 2025 at 3:03 PM
Exciting news - we are recruiting new Group Leaders! 🥼
We are seeking to appoint exceptional early-career scientists & clinician scientists as #GroupLeaders to develop bold, innovative, high-impact #CancerResearch programmes
Full details on our website: www.cruk.manchester.ac.uk/career/new-g...
We are seeking to appoint exceptional early-career scientists & clinician scientists as #GroupLeaders to develop bold, innovative, high-impact #CancerResearch programmes
Full details on our website: www.cruk.manchester.ac.uk/career/new-g...
The Garnett Lab is excited to launch DepMap Miner, a new tool to explore cancer dependency data!
Built on the Sanger DepMap, the DepMap Miner brings together multi-omic and functional datasets for over 1300 cancer cell models.
Start mining data now: dataminer.depmap.sanger.ac.uk
Built on the Sanger DepMap, the DepMap Miner brings together multi-omic and functional datasets for over 1300 cancer cell models.
Start mining data now: dataminer.depmap.sanger.ac.uk
September 20, 2025 at 7:43 AM
The Garnett Lab is excited to launch DepMap Miner, a new tool to explore cancer dependency data!
Built on the Sanger DepMap, the DepMap Miner brings together multi-omic and functional datasets for over 1300 cancer cell models.
Start mining data now: dataminer.depmap.sanger.ac.uk
Built on the Sanger DepMap, the DepMap Miner brings together multi-omic and functional datasets for over 1300 cancer cell models.
Start mining data now: dataminer.depmap.sanger.ac.uk
Reposted by Mathew Garnett
Exciting FULL PROFESSORSHIP at the Vienna BioCenter - Molecular Mechanisms of Disease Mechanisms: www.maxperutzlabs.ac.at/news/open-po... Come be our colleague!
Full Professorship in Molecular Mechanisms of Disease
The Max Perutz Labs - one of Europe’s leading institutes for basic research in the life sciences - invite applications for a Full Professorship in Molecular Mechanisms of Disease. We are seeking outst...
www.maxperutzlabs.ac.at
September 4, 2025 at 10:25 AM
Exciting FULL PROFESSORSHIP at the Vienna BioCenter - Molecular Mechanisms of Disease Mechanisms: www.maxperutzlabs.ac.at/news/open-po... Come be our colleague!
Excited to be on my was to the GRC synthetic lethal approaches in oncology conference #GRCSyntheticLethal. Some stellar science kicking off tonight. In the meantime enjoying the beautiful scenery on the drive up the Maine coast.
July 20, 2025 at 5:36 PM
Excited to be on my was to the GRC synthetic lethal approaches in oncology conference #GRCSyntheticLethal. Some stellar science kicking off tonight. In the meantime enjoying the beautiful scenery on the drive up the Maine coast.
Reposted by Mathew Garnett
A new drug target that has the potential to treat aggressive eye cancer has been discovered 👁️
This research may provide a hopeful outlook for eye cancer patients with very limited treatment options and has implications for a range of other cancers ⤵️
www.sanger.ac.uk/news_item/ne...
This research may provide a hopeful outlook for eye cancer patients with very limited treatment options and has implications for a range of other cancers ⤵️
www.sanger.ac.uk/news_item/ne...
July 4, 2025 at 10:37 AM
A new drug target that has the potential to treat aggressive eye cancer has been discovered 👁️
This research may provide a hopeful outlook for eye cancer patients with very limited treatment options and has implications for a range of other cancers ⤵️
www.sanger.ac.uk/news_item/ne...
This research may provide a hopeful outlook for eye cancer patients with very limited treatment options and has implications for a range of other cancers ⤵️
www.sanger.ac.uk/news_item/ne...
Reposted by Mathew Garnett
Join the Frontier of Cellular Genomics at Wellcome Sanger Institute. We are looking for Group Leaders to drive innovative science with core funding, cutting-edge technology, and global impact.
Apply now: lnkd.in/eqneJFVt
📅 Closing date: 17 August
#GroupLeader #FacultyPosition #CambridgeScience
Apply now: lnkd.in/eqneJFVt
📅 Closing date: 17 August
#GroupLeader #FacultyPosition #CambridgeScience
June 25, 2025 at 9:06 AM
Join the Frontier of Cellular Genomics at Wellcome Sanger Institute. We are looking for Group Leaders to drive innovative science with core funding, cutting-edge technology, and global impact.
Apply now: lnkd.in/eqneJFVt
📅 Closing date: 17 August
#GroupLeader #FacultyPosition #CambridgeScience
Apply now: lnkd.in/eqneJFVt
📅 Closing date: 17 August
#GroupLeader #FacultyPosition #CambridgeScience
Reposted by Mathew Garnett
Now online in Cancer Discovery: AAnet Resolves a Continuum of Spatially-Localized Cell States to Unveil Intratumoral Heterogeneity - by Aarthi Venkat, Scott Youlten, Beatriz San Juan, Smita Krishnaswamy, Christine Chaffer, and colleagues doi.org/10.1158/2159...
June 24, 2025 at 6:31 PM
Now online in Cancer Discovery: AAnet Resolves a Continuum of Spatially-Localized Cell States to Unveil Intratumoral Heterogeneity - by Aarthi Venkat, Scott Youlten, Beatriz San Juan, Smita Krishnaswamy, Christine Chaffer, and colleagues doi.org/10.1158/2159...
Reposted by Mathew Garnett
Cancer Plasticity Atlas To Improve Cancer Therapies
#HelmholtzMunich joins @sangerinstitute.bsky.social & @parse.bsky.social to build the Cancer Plasticity Atlas, using #AI & single-cell data to model therapy response.
👉 t1p.de/13ifi
@fabiantheis.bsky.social
@mgarnett.bsky.social
#CancerResearch
#HelmholtzMunich joins @sangerinstitute.bsky.social & @parse.bsky.social to build the Cancer Plasticity Atlas, using #AI & single-cell data to model therapy response.
👉 t1p.de/13ifi
@fabiantheis.bsky.social
@mgarnett.bsky.social
#CancerResearch
June 13, 2025 at 6:27 AM
Cancer Plasticity Atlas To Improve Cancer Therapies
#HelmholtzMunich joins @sangerinstitute.bsky.social & @parse.bsky.social to build the Cancer Plasticity Atlas, using #AI & single-cell data to model therapy response.
👉 t1p.de/13ifi
@fabiantheis.bsky.social
@mgarnett.bsky.social
#CancerResearch
#HelmholtzMunich joins @sangerinstitute.bsky.social & @parse.bsky.social to build the Cancer Plasticity Atlas, using #AI & single-cell data to model therapy response.
👉 t1p.de/13ifi
@fabiantheis.bsky.social
@mgarnett.bsky.social
#CancerResearch
Reposted by Mathew Garnett
Announcing a new collaboration with @parse.bsky.social @www.helmholtz-munich.de to develop a #Cancer Plasticity Atlas.
The reference map will help predict the effect of cancer drugs - where resistance might develop and where to target future treatment efforts.
www.sanger.ac.uk/news_item/pi...
The reference map will help predict the effect of cancer drugs - where resistance might develop and where to target future treatment efforts.
www.sanger.ac.uk/news_item/pi...
Pioneering cancer plasticity atlas will help predict response to cancer therapies
Utilising novel organoid perturbation and Artificial Intelligence (AI) platforms, the aim is to create a comprehensive dataset to fuel foundational drug discovery models and cancer research.
www.sanger.ac.uk
June 12, 2025 at 4:17 PM
Announcing a new collaboration with @parse.bsky.social @www.helmholtz-munich.de to develop a #Cancer Plasticity Atlas.
The reference map will help predict the effect of cancer drugs - where resistance might develop and where to target future treatment efforts.
www.sanger.ac.uk/news_item/pi...
The reference map will help predict the effect of cancer drugs - where resistance might develop and where to target future treatment efforts.
www.sanger.ac.uk/news_item/pi...
This is going to be a great event showcasing cutting edge science.
🧬 Excited to announce the 2nd Euro Cancer DepMap Symposium bringing together leading minds in functional genomics, cancer vulnerabilities, AI, CRISPR and anti-cancer target discovery.📍Join us in Milan for cutting-edge science, open discussion & collaboration. #EuroDepMap #CancerResearch #CRISPR
June 12, 2025 at 11:59 AM
This is going to be a great event showcasing cutting edge science.
Don't miss your chance to register for the GRC conference on Synthetic Lethality Approaches in Oncology this July in beautiful Maine (near Boston). We have stellar speakers, with a mix from academia and industry in this translational space. There are speaker slots from abstracts.
June 6, 2025 at 7:04 AM
Don't miss your chance to register for the GRC conference on Synthetic Lethality Approaches in Oncology this July in beautiful Maine (near Boston). We have stellar speakers, with a mix from academia and industry in this translational space. There are speaker slots from abstracts.
Reposted by Mathew Garnett
MLOmics: Cancer Multi-Omics Database for Machine Learning 🧪 🧬🖥️ www.nature.com/articles/s41...
MLOmics: Cancer Multi-Omics Database for Machine Learning - Scientific Data
Scientific Data - MLOmics: Cancer Multi-Omics Database for Machine Learning
www.nature.com
May 31, 2025 at 7:13 AM
MLOmics: Cancer Multi-Omics Database for Machine Learning 🧪 🧬🖥️ www.nature.com/articles/s41...
For students & trainees, there are speaking slots for selected abstracts at the upcoming GRC conference on Synthetic Lethality in Oncology (www.grc.org/synthetic-le...). The informal small meeting format is perfect for networking and to find your next career opportunity. Bursaries available.
May 27, 2025 at 9:27 AM
For students & trainees, there are speaking slots for selected abstracts at the upcoming GRC conference on Synthetic Lethality in Oncology (www.grc.org/synthetic-le...). The informal small meeting format is perfect for networking and to find your next career opportunity. Bursaries available.
Check out the first session for the upcoming GRC conference on synthetic lethality in oncology www.grc.org/synthetic-le.... Top flight speakers - Simon Powell (MSK), Chris Lord (ICR), and plenary talk from William Sellers (Broad Inst.). What a start! It's not too late to register.
May 22, 2025 at 4:51 PM
Check out the first session for the upcoming GRC conference on synthetic lethality in oncology www.grc.org/synthetic-le.... Top flight speakers - Simon Powell (MSK), Chris Lord (ICR), and plenary talk from William Sellers (Broad Inst.). What a start! It's not too late to register.
Check this out if you're interested in #crispr #baseeditor. Congratulations Cansu for creating this wonderful tool.
🚨 Excited to share our latest preprint!
@mgarnett.bsky.social @mattcoelho.bsky.social
We introduce BEstimate, a flexible, comprehensive tool for designing and interpreting CRISPR-based editing experiments.
#CRISPR #BEstimate #BaseEditor
@mgarnett.bsky.social @mattcoelho.bsky.social
We introduce BEstimate, a flexible, comprehensive tool for designing and interpreting CRISPR-based editing experiments.
#CRISPR #BEstimate #BaseEditor
BEstimate: a computational tool for the design and interpretation of CRISPR base editing experiments https://www.biorxiv.org/content/10.1101/2025.05.19.654892v1
May 22, 2025 at 4:48 PM
Check this out if you're interested in #crispr #baseeditor. Congratulations Cansu for creating this wonderful tool.
Reposted by Mathew Garnett
Today, the ERC formally adopted a decision to increase its support for researchers moving to Europe.
On top of its normal grants, the ERC offers 'start-up' funding to help PIs establish laboratories / research teams in Europe.
This extra funding is now x2 (up to €2 million!)
europa.eu/!6Vdgmp
On top of its normal grants, the ERC offers 'start-up' funding to help PIs establish laboratories / research teams in Europe.
This extra funding is now x2 (up to €2 million!)
europa.eu/!6Vdgmp
May 16, 2025 at 10:58 AM
Today, the ERC formally adopted a decision to increase its support for researchers moving to Europe.
On top of its normal grants, the ERC offers 'start-up' funding to help PIs establish laboratories / research teams in Europe.
This extra funding is now x2 (up to €2 million!)
europa.eu/!6Vdgmp
On top of its normal grants, the ERC offers 'start-up' funding to help PIs establish laboratories / research teams in Europe.
This extra funding is now x2 (up to €2 million!)
europa.eu/!6Vdgmp
Learn about the future of synthetic lethality in oncology at the upcoming Gordon Research Conference. This is the inaugural meeting and WOW what a lineup! We have a truly phenomenal program, with top speakers from academia and industry. Check it out at the link below.
www.grc.org/synthetic-le....
www.grc.org/synthetic-le....
2025 Synthetic Lethality Approaches in Oncology Conference GRC
The 2025 Gordon Research Conference on Synthetic Lethality Approaches in Oncology will be held in Portland, Maine. Apply today to reserve your spot.
www.grc.org
May 12, 2025 at 8:11 PM
Learn about the future of synthetic lethality in oncology at the upcoming Gordon Research Conference. This is the inaugural meeting and WOW what a lineup! We have a truly phenomenal program, with top speakers from academia and industry. Check it out at the link below.
www.grc.org/synthetic-le....
www.grc.org/synthetic-le....
Reposted by Mathew Garnett
Choose Science. Choose Europe.
A new Marie Skłodowska-Curie Actions Postdoctoral Fellowships 2025 call is now open.
With a budget of €404.3 million, it will support around 1,650 researchers from Europe and beyond.
Apply by 10 September → europa.eu/!fBTMgF
A new Marie Skłodowska-Curie Actions Postdoctoral Fellowships 2025 call is now open.
With a budget of €404.3 million, it will support around 1,650 researchers from Europe and beyond.
Apply by 10 September → europa.eu/!fBTMgF
May 8, 2025 at 10:12 AM
Choose Science. Choose Europe.
A new Marie Skłodowska-Curie Actions Postdoctoral Fellowships 2025 call is now open.
With a budget of €404.3 million, it will support around 1,650 researchers from Europe and beyond.
Apply by 10 September → europa.eu/!fBTMgF
A new Marie Skłodowska-Curie Actions Postdoctoral Fellowships 2025 call is now open.
With a budget of €404.3 million, it will support around 1,650 researchers from Europe and beyond.
Apply by 10 September → europa.eu/!fBTMgF
Reposted by Mathew Garnett
My dept in London at Imperial (Bioengineering) is recruiting a group leader at Professor level 🧑🎓 Please RT. It's a great place with world-class expertise in all sorts of biomedical & biological engineering topics like synthetic biology. It's also not in the USA. www.imperial.ac.uk/jobs/search-...
May 2, 2025 at 3:20 PM
My dept in London at Imperial (Bioengineering) is recruiting a group leader at Professor level 🧑🎓 Please RT. It's a great place with world-class expertise in all sorts of biomedical & biological engineering topics like synthetic biology. It's also not in the USA. www.imperial.ac.uk/jobs/search-...
Reposted by Mathew Garnett
Great talk by Yanhua Rao at #AACR2025 on GSK’s new clinical WRN inhibitor. Proud to see our unpublished data spotlighted for revealing new MoA insights. Exciting times ahead! @mgarnett.bsky.social
April 28, 2025 at 6:16 PM
Great talk by Yanhua Rao at #AACR2025 on GSK’s new clinical WRN inhibitor. Proud to see our unpublished data spotlighted for revealing new MoA insights. Exciting times ahead! @mgarnett.bsky.social
Six years after the discovery of WRN synthetic lethality in MSI cancers, WRN inhibitors hit center stage again today at #aacr25 with report of the first in human phase 1 trial data for RO7589831. Can’t wait to see it!
April 27, 2025 at 2:38 PM
Six years after the discovery of WRN synthetic lethality in MSI cancers, WRN inhibitors hit center stage again today at #aacr25 with report of the first in human phase 1 trial data for RO7589831. Can’t wait to see it!
Reposted by Mathew Garnett
I am speaking at #AACR25 this afternoon on our latest work on somatic mutations in normal tissues. If you are attending AACR, feel free to drop by and say hello.
brnw.ch/21wRUZZ
brnw.ch/21wRUZZ
April 26, 2025 at 10:10 AM
I am speaking at #AACR25 this afternoon on our latest work on somatic mutations in normal tissues. If you are attending AACR, feel free to drop by and say hello.
brnw.ch/21wRUZZ
brnw.ch/21wRUZZ
Reposted by Mathew Garnett
Just landed in Chicago for #AACR25 — Millennium Park in bloom! Excited for team talks on WRN inhibitors in MSI cancers, with first-in-human data discussed by @mgarnett.bsky.social at the Clinical Trials Plenary. I’ll present new data on WRNi-driven evolution — Poster #420! #MSI #SyntheticLethality
April 25, 2025 at 4:02 PM
Just landed in Chicago for #AACR25 — Millennium Park in bloom! Excited for team talks on WRN inhibitors in MSI cancers, with first-in-human data discussed by @mgarnett.bsky.social at the Clinical Trials Plenary. I’ll present new data on WRNi-driven evolution — Poster #420! #MSI #SyntheticLethality
Reposted by Mathew Garnett
Excited to announce our preprint today @biorxivpreprint.bsky.social
Using functional genomics, we map the genetic determinants cancer cell sensitivity to tumour-reactive T cells:
www.biorxiv.org/content/10.1...
Using functional genomics, we map the genetic determinants cancer cell sensitivity to tumour-reactive T cells:
www.biorxiv.org/content/10.1...
CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance
Cancer immunotherapy is only effective in a subset of patients, highlighting the need for effective biomarkers and combination therapies. Here we systematically identify genetic determinants of cancer...
www.biorxiv.org
April 22, 2025 at 7:56 AM
Excited to announce our preprint today @biorxivpreprint.bsky.social
Using functional genomics, we map the genetic determinants cancer cell sensitivity to tumour-reactive T cells:
www.biorxiv.org/content/10.1...
Using functional genomics, we map the genetic determinants cancer cell sensitivity to tumour-reactive T cells:
www.biorxiv.org/content/10.1...
Reposted by Mathew Garnett
Uncovering synthetic lethal vulnerabilities across cancers. Upregulation of #TWIST1/2, #VIM, and integrin components ( #ITGB5, #ITGAV, #FERMT2 ) constitutes a synthetic lethal buffering mechanism that preserves tumor fitness despite #CDH1 #Ecadherin loss #lobular #DGC
www.nature.com/articles/s41...
www.nature.com/articles/s41...
The transcriptomic architecture of common cancers reflects synthetic lethal interactions - Nature Genetics
Tumor cells upregulate compensatory buffering genes following tumor suppressor loss. These genes may represent new synthetic lethal partners that could be harnessed therapeutically.
www.nature.com
April 18, 2025 at 9:11 PM
Uncovering synthetic lethal vulnerabilities across cancers. Upregulation of #TWIST1/2, #VIM, and integrin components ( #ITGB5, #ITGAV, #FERMT2 ) constitutes a synthetic lethal buffering mechanism that preserves tumor fitness despite #CDH1 #Ecadherin loss #lobular #DGC
www.nature.com/articles/s41...
www.nature.com/articles/s41...